Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention
Article Number: SIS718396AI050825
5th August, 2025
Author(s):
Clifford J. Rosen, Julie R. Ingelfinger
Abstract:
This editorial explores the progress and challenges in preventing type 1 diabetes mellitus (T1DM), an autoimmune disease targeting pancreatic beta cells. The authors highlight a phase 2 trial of teplizumab, an anti CD3 monoclonal antibody, which delayed T1DM onset in high risk individuals (stage 2) by nearly two years compared to placebo (median time to diagnosis: 48.4 vs. 24.4 months; hazard ratio 0.41). While the results underscore the potential of immune modulation, limitations include the small trial size (76 participants), single short term treatment course, and unresolved questions about long term efficacy and safety. The study advances understanding of T1DM pathogenesis but emphasizes the need for refined screening and targeted therapies.